

Press Release

Nicox's Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024

- **Shareholders adopted all resolutions proposed by the Board of Directors at the Ordinary and Extraordinary General Meetings**

May 6, 2024 – release at 17h45 CET
Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, announced that the Ordinary and Extraordinary General Meetings were held today, on second convening.

The general meetings were held in the presence of SCP EZAVIN-THOMAS, in the person of Maître Nathalie Thomas, in their capacity as *ad hoc* agent to represent non-voting shareholders at the general meetings. SCP EZAVIN-THOMAS was appointed by order of the President of the Commercial Court of Antibes in a second decision on April 25, 2024, in replacement of SELARL XAVIER HUERTAS & ASSOCIES, in the person of Maître Xavier Huertas, initially appointed by the President of the Commercial Court of Antibes on April 18, 2024.

Including the presence of Maître Nathalie Thomas, in accordance with the terms of the orders of the President of the Commercial Court of Antibes of the April 18 and 25 2024, the quorum, which was initially at 18,73% was brought to 100% of the shares eligible to vote.

The shareholders of Nicox adopted the ordinary and extraordinary resolution proposed by the Board of Directors, notably:

- The ratification of the transfer of the registered office to Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois, 06410 Biot;
- The reduction of the share capital due to losses by reducing the nominal value of the shares from €1 to €0.01;
- the financial authorisations granted to the Board of Directors to carry out capital increases with or without preferential subscription rights;
- the authorization given to the Board of directors to grant free shares and/or stock options to the Company's employees and corporate officers;
- Resolutions relating to the agreement with BlackRock Inc. (cf press release of February 28, 2024), namely:
 - the appointment of Mrs. Sonia Benhamida and Mr. Maurizio Petitbon as observers;
 - the authorisation granted to the Board of Directors to issue bonds convertible into shares.

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIAE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index.

For more information www.nicox.com

Analyst coverage

Bryan, Garnier & Co
H.C. Wainwright & Co

Eric Yoo
Yi Chen

Paris, France
New York, U.S.



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox

Gavin Spencer
Chief Executive Officer
+33 (0)4 97 24 53 00
communications@nicox.com

Media / Investors

Sophie Baumont
Cohesion Bureau
+33 6 27 74 74 49
sophie.baumont@cohesionbureau.com

Nicox S.A.

Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00